{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:19:00Z","timestamp":1771877940246,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the relationship between the implantation position of dexamethasone intravitreal implant (DEX-I) and post-injection intraocular pressure (IOP) elevation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included 324 patients (332 eyes) who received at least one DEX-I injection between June 2020 and June 2024, with a follow-up period of at least 3 months. Patient demographics, diagnoses, and DEX-I implantation positions were recorded. The correlation between implantation position and post-injection IOP elevation was analyzed. IOP elevation was defined as an IOP greater than 25\u202fmmHg and\/or an increase of 10\u202fmmHg from baseline. DEX-I implantation positions were defined as follows: P1: implant located in the vitreous near the ciliary body, anterior to the ora serrata (with or without ciliary body contact); P2: implant located in the vitreous from the ora serrata to the pre-equatorial region; P3: implant located in the post-equatorial vitreous. The equator was defined by the vortex veins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the follow-up period, 68 eyes (20.48%) experienced IOP elevation. Compared to P2 and P3, the P1 implantation position was significantly associated with a higher incidence of IOP elevation (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) and was positively correlated with early IOP elevation (within 15\u202fdays post-injection) (<jats:italic>r<\/jats:italic>\u202f=\u202f0.761; <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The P1 implantation is positively correlated with IOP elevation, particularly with early IOP elevation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1582422","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:59:39Z","timestamp":1757311179000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The relationship between the intraocular position of dexamethasone intravitreal implant and post-injection intraocular pressure elevation"],"prefix":"10.3389","volume":"12","author":[{"given":"Dingxi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jcjo.2015.01.007","article-title":"Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children","volume":"50","author":"Lei","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year,randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00417-018-4095-5","article-title":"Response to safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience","volume":"256","author":"Blanc","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/jop.2012.0253","article-title":"Secondary glaucoma after intravitreal dexamethasone 0.7 Mg implant in patients with retinal vein occlusion: a one-year follow-up","volume":"29","author":"Meyer","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/bjophthalmol-2019-313991","article-title":"Safety of 6000 intravitreal dexamethasone implants","volume":"104","author":"Rajesh","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1097\/IAE.0000000000000726","article-title":"Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations","volume":"35","author":"Yang","year":"2015","journal-title":"Retina"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"626.e2","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","article-title":"Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial","volume":"118","author":"Pearson","year":"2011","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","article-title":"Intraocular pressure monitoring post intravitreal steroids: a systematic review","volume":"58","author":"Kiddee","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.4103\/ijo.IJO_3479_20","article-title":"Clinical implications of energy used in neodymium: yttrium aluminum garnet posterior capsulotomy on intraocular pressure","volume":"69","author":"Chawla","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1097\/IAE.0000000000001364","article-title":"Ocular hypertension after intravitreal dexamethasone (OZURDEX) sustained-release implant","volume":"37","author":"Chin","year":"2017","journal-title":"Retina"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","article-title":"Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema","volume":"128","author":"Haller","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3390\/cells12202452","article-title":"Role of glucocorticoids and glucocorticoid receptors in Glaucoma pathogenesis","volume":"12","author":"Patel","year":"2023","journal-title":"Cells"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","article-title":"Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension","volume":"37","author":"Malcl\u00e8s","year":"2017","journal-title":"Retina"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.ajo.2014.09.003","article-title":"Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency","volume":"158","author":"Zarranz-Ventura","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/eye.2013.79","article-title":"Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion","volume":"27","author":"Mayer","year":"2013","journal-title":"Eye"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1167\/iovs.07-1279","article-title":"FK 506-binding protein 51 regulates nuclear transport of the glucocorticoid receptor beta and glucocorticoid responsiveness","volume":"49","author":"Zhang","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1350-9462(98)00035-4","article-title":"Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma","volume":"18","author":"Wordinger","year":"1999","journal-title":"Prog Retin Eye Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/archopht.1997.01100150377011","article-title":"Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids","volume":"115","author":"Johnson","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1097\/IAE.0000000000001883","article-title":"Intraocular dexamethasone implant position in situ and ocular hypertension","volume":"38","author":"Sudhalkar","year":"2018","journal-title":"Retina"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1038\/s41433-024-03205-y","article-title":"Optimizing open-angle glaucoma risk assessment in patients with retinal vein occlusions","volume":"38","author":"Muhtaseb","year":"2024","journal-title":"Eye"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1582422\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:59:41Z","timestamp":1757311181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1582422\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":22,"alternative-id":["10.3389\/fmed.2025.1582422"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1582422","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"article-number":"1582422"}}